-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 17, the CDE official website showed that Pfizer's PF-06882961 tablet (danuglipron) clinical trial application has been granted the default permission, and it plans to conduct clinical research on the treatment of type 2 diabetes.
Danuglipron (code name: PF-06882961 tablets) is an oral small molecule GLP-1 receptor agonist developed by Pfizer.
The potential advantages of danuglipron include: ① It can achieve effective control of blood sugar and weight; ② Tolerability and safety are similar to peptide GLP-1RA, and the oral dosage form is convenient to take; ③ Good bioavailability; ④ Different from oral macromolecules GLP-1RA is not restricted by food or dosage.
Pfizer announced at the online Investor Day event (Investor Day) held in August 2020
danuglipron Phase I clinical study data.
At present, Pfizer has launched a phase II clinical study to test the effect of danuglipron in the treatment of diabetic patients.
Prior to this, Novo Nordisk Rybelsus (oral smeglutide, once a day) has been approved for marketing by the FDA and is currently the only oral GLP-1 receptor agonist on the market.
